REGN stock forecast, quote, news & analysis

Key Takeaways

• Regeneron Pharmaceuticals (REGN) rallied approximately 11% over the past 30 days, climbing from roughly $610 to $677 as of mid-July 2026.
• The rebound follows a sharp May selloff triggered by the Phase III fianlimab-Libtayo melanoma trial failing to meet its primary endpoint.
• Strong Q1 2026 earnings — $9.47 EPS on $3.61 billion in revenue, both exceeding consensus — continue to support investor confidence in the core business.
• Pipeline catalysts, including FDA Priority Review for cemdisiran in generalized myasthenia gravis and expanded oncology partnerships, have helped shift sentiment.
• Institutional accumulation remains robust, with CalPERS increasing its stake by 8.8% and overall institutional ownership standing above 83%.
• Analysts maintain a consensus "Moderate Buy" rating with an average 12-month price target near $788, implying further potential upside from current levels.

Regeneron Pharmaceuticals (REGN) Company Overview and Market Position

Regeneron Pharmaceuticals, Inc. is a leading U.S.-based biotechnology company headquartered in Tarrytown, New York. Founded in 1988, the company discovers, develops, manufactures, and commercializes biologic medicines targeting serious diseases across ophthalmology, immunology, oncology, cardiovascular disease, and rare genetic disorders. Regeneron's flagship products include Eylea and Eylea HD for retinal diseases, Dupixent — co-developed with Sanofi — for atopic dermatitis, asthma, and other type 2 inflammatory conditions, and Libtayo in immuno-oncology. The company's proprietary VelocImmune platform has been foundational in generating fully human monoclonal antibodies. With a market capitalization exceeding $71 billion, a debt-to-equity ratio of just 0.06, and more than $15 billion in cash and marketable securities net of debt, Regeneron is widely regarded as one of the most financially resilient biotech enterprises in the sector.

Regeneron Pharmaceuticals (REGN) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, REGN shares advanced approximately 11%, rising from a closing price of $609.94 on June 18, 2026, to $676.69 as of the market close on July 17, 2026. The stock's 50-day simple moving average sits near $641, meaning the recent rally has pushed shares comfortably above short-term trend levels. The move marks a meaningful recovery from the multi-month lows reached in late June.

Zooming out to the full quarter, the stock's path has been far more turbulent. In late April, REGN traded near $732 before a series of negative catalysts triggered a steep decline. The quarter's low point arrived around $595 in intraday trading on June 22, representing a peak-to-trough drawdown of roughly 19% within approximately eight weeks. The stock has since rebounded roughly 14% from those lows, though it remains well below its 52-week high of $821.11 and its 200-day simple moving average of roughly $718. The quarterly trend, therefore, reflects a sharp selloff followed by a partial but notable recovery, with the 30-day window capturing the majority of that bounce.

What Drove REGN Stock Price in the Last 30 Days

Several verified developments contributed to Regeneron's double-digit advance over the past month. First, the stock entered the period in deeply oversold territory after the Phase III fianlimab-Libtayo trial failure in May erased nearly 10% of market value in a single session. Value-oriented institutional buying — including a disclosed 8.8% stake increase by the California Public Employees' Retirement System (CalPERS) — provided a floor and signaled long-term conviction in the company's fundamentals.

Second, Regeneron expanded its oncology collaboration with CytomX Therapeutics (CTMX) in a deal potentially worth up to $4 billion in milestone payments and royalties, focused on conditionally activated bispecific cancer therapies. This underscored the company's commitment to rebuilding pipeline momentum after the fianlimab setback.

Third, regulatory progress on multiple fronts — including FDA acceptance with Priority Review for cemdisiran in generalized myasthenia gravis, EMA accelerated assessment for Otarmeni as a gene therapy for genetic hearing loss, and a garetosmab PDUFA date in August 2026 — reminded investors of the breadth of Regeneron's late-stage pipeline. Meanwhile, Dupixent continued to deliver, with global net sales running at an annualized pace near $20 billion, a powerful reminder that the company's core immunology franchise remains robust.

What Drove REGN Stock Performance Over the Last Quarter

The broader quarterly narrative was dominated by the fianlimab clinical failure. On April 29, 2026, during the Q1 earnings call, management disclosed that the Phase III fianlimab-Libtayo study had been altered to expand the patient population eligible for progression-free survival analysis. Shares fell roughly 6.2% that day. Then, on May 15, Regeneron announced the trial definitively missed its primary endpoint of statistically significant improvement in PFS versus Merck's (MRK) Keytruda monotherapy. The stock dropped an additional 9.8%, settling near $630.

Despite the pipeline disappointment, Regeneron's Q1 financial results provided a strong counter-narrative: revenue grew 19% year-over-year to $3.61 billion, Dupixent collaboration profits rose 42%, and the company authorized a new $3 billion share repurchase program. The selloff in May was followed by cautious dip-buying in June and a more decisive recovery in July, as analysts recalibrated target prices — several remaining above $750 — and investors refocused on the durability of the commercial portfolio. The quarter thus illustrates a classic biotech pattern: acute pipeline-driven downside, followed by fundamental-driven recovery.

Trending AI Robots

For traders seeking data-driven insights amid volatile biotech swings, Tickeron's Trending AI Robots page offers a curated selection of top-performing AI trading bots. Tickeron hosts hundreds of automated trading bots that actively trade thousands of tickers across diverse strategies and timeframes, but only those with the strongest real-time performance metrics and relevance to current market conditions appear in this section. Each bot is built around a distinct technical, fundamental, or pattern-based strategy, allowing users to compare approaches and identify those aligned with their trading style. Exploring the Trending AI Robots page can serve as a practical starting point for incorporating algorithmic insight into a broader investment research process.

REGN Stock Forecast Drivers: What Investors Should Watch Next

Regeneron's upcoming Q2 2026 earnings report, confirmed for July 30, 2026, represents the most immediate catalyst. Consensus EPS sits at $10.85, and investors will closely scrutinize Eylea HD prescription trends, Dupixent growth trajectory, and any updates on the $3 billion buyback program. Management previously guided for a temporary Q2 gross margin headwind tied to a manufacturing interruption at the Limerick facility, making margin recovery commentary particularly important.

Beyond earnings, key regulatory milestones loom: an FDA decision on Eylea HD prefilled syringe formulations is expected during the current quarter, the garetosmab PDUFA date arrives in August, and cemdisiran's FDA decision is anticipated in Q4 2026. On the competitive front, ongoing encroachment from Roche's Vabysmo in the retinal disease market, biosimilar threats to the legacy Eylea franchise, and potential Medicare drug price negotiation rules remain material risks. The ongoing securities class action related to fianlimab disclosures adds a layer of legal uncertainty, though no financial impact has been quantified. Investors should also monitor any strategic business development moves, as Regeneron's robust $15.8 billion net cash position provides ample capacity for pipeline-enhancing acquisitions or partnerships.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations